Eisai and Biogen have received approval in Japan for LEQEMBI Pen, a subcutaneous autoinjector formulation of lecanemab f...
Lundbeck has received marketing authorisation from Japan’s Ministry of Health, Labour and Welfare for Vyepti, or e...
Akeso has received clearance from the Center for Drug Evaluation under China’s National Medical Products Administr...
Researchers from the National University of Singapore have demonstrated a non-invasive approach using pulsed electromagn...
Australia-based Telix Pharmaceuticals has announced that the United States (US) Food and Drug Administration (FDA) has a...
China Medical System Holdings has announced that initial prescriptions for Silevimig Injection have been issued at multi...
Minoryx Therapeutics and Neuraxpharm have completed enrolment in the global Phase III CALYX trial evaluating leriglitazo...
Alebund Pharmaceuticals has received clearance from the US Food and Drug Administration for the Investigational New Drug...
Everest Medicines has received approval from China’s National Medical Products Administration for CARDAMYST, or et...
Everest Medicines has announced that China’s National Medical Products Administration has accepted the Biologics L...
Ascletis Pharma has dosed the first participant in its global Phase III clinical programme evaluating ASC30, an investig...
Fosun Pharma continued to strengthen its innovation-led growth strategy in the first half of 2026, supported by increasi...
Orasis Pharmaceuticals and Aspen Australia have announced submission of a New Drug Application in Australia for BESKA, p...
The pharmaceutical industry’s innovation equation is changing. Developing an entirely new molecu...
Brii Biosciences has reported topline end-of-treatment data from its ongoing Phase 2b ENRICH and ENHANCE studies evaluat...
Ascletis Pharma has submitted two Investigational New Drug applications to the U.S. FDA for obesity treatment candidates...
Viking Therapeutics has initiated a Phase 1 clinical study of VK3019, an investigational dual amylin and calcitonin rece...
Servier has enrolled the first U.S. patient in a Phase Ib/II first-in-human clinical study evaluating an investigational...
As the pharmaceutical industry advances towards increasingly complex, poorly soluble drug candidates, formulation has ...
Lys Therapeutics has raised more than €25 million since its founding in 2021 to advance LYS241, its lead neurovascu...
SystImmune and parent company Sichuan Biokin Pharmaceutical have received regulatory approval in China for iza-bren, als...
The Tang Prize Foundation has awarded the 2026 Tang Prize in Biopharmaceutical Science to three pioneers of cellular imm...
MindWalk Holdings Corp. is positioning biological data infrastructure as a key bottleneck in AI-enabled drug discovery, ...
Neurocrine Biosciences has presented the first retrospective case series of CRENESSITY in patients with classic congenit...
Nuvalent has received U.S. FDA acceptance and Priority Review for its New Drug Application for neladalkib in tyrosine ki...
